Revolutionizing developments in biological tissue vales will drive the European transcatheter heart valve implantation market to over $1.7 Billion by 2020
According to a new report on the European Market for Cardiac Surgery Devices by iData Research (www.idataresearch.com), the leading global authority in medical device and pharmaceutical market research, the total European Cardiac Surgery Devices market is projected to grow to over $3.4 Billion by 2020. The strongest market fueling this growth is the transcatheter heart valve devices, which is comprised of both the transcatheter heart valve implantation (THVI) and the transcatheter mitral valve repair (TMVR) segments. Currently, the only THVI product available on the market is transcatheter aortic valve implantation (TAVI) devices. However transcatheter mitral valve implantation (TMVI) devices are being developed and are expected to receive CE approval by 2020.
With an aging population and increasing prevalence of obesity, the number of patients suffering from heart failure in Europe will continue to grow. Mitral regurgitation (MR) is the second most common heart valve disease in Europe and affects millions of patients worldwide. “TMVR is a less invasive treatment option for MR than open surgery making it more appealing for patients,” noted Dr. Kamarn Zamanian, CEO of iData. “These factors will continue to drive the market which is projected to grow to over 12% by 2020.” There are currently only two players in this market, Abbott with their MitraClip™, the world’s first TMVR device, and Cardiac Dimensions.
The transcathether heart valve implantation device market is expected to grow over 10% by 2020. This market is comprised of the transcatheter aortic valve implantation (TAVI) and the transcathether mitral valve implantation (TMVI). As of 2013 only TAVI products have been approved in Europe. Leading the TAVI market is Edwards Lifesciences, who recently introduced their new product SAPIEN 3®, Boston Scientific, recently received CE market certification for its Lotus™ Valve System as well as, Medtronic, JenaValve, St Jude Medical, Sorin and Direct Flow Medical.
Recent developments for the treatment of aortic heart valve conditions have been generating much interest amongst the international cardiac community. Biological tissue valves is a newer and a less invasive treatment option for aortic heart valve conditions as opposed to the traditional open surgery.
Tissue valves have been gaining popularity over the alternative mechanical valves. They are biocompatible and do not require a lifelong treatment of medication. TAVI procedures are an appealing treatment option for patients with late stage heart failure and or are too ill to undergo a more invasive treatment.
The global series “Markets for Cardiac Surgery Devices” covering the U.S., Asia and 15 countries in Europe. The full reports provide a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market share and analysis of major plays’ success strategies in each market and segment.
The report also covers markets for: tissue heart valve, mechanical heart valve, annuloplasty repair, transcatheter mitral valve repair (TMVR), transcatheter heart valve implantation (THVI), on-pump CABG, off-pump CABG, endoscopic vessel harvesting (EVH), anastomosis assist, cardiac ablation, transmyocardial revascularization (TMR), ventricular assist device (VAD), intra-aortic balloon pump (IABP), artificial heart, patent foramen ovale (PFO), atrial sept defect (ASD) and ventricular septal defect (VSD) device markets.
For a free synopisis of this report please register here